Franklin Rosenblat, DO
Infectious Disease · Pontiac, MINPI 1689671281
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $959 of the $1,181 with a category attached, or 81.2%. It is spread thinly across 15 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $377 and has fallen 94.6% since, to $20 in 2024.
Across 54 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$230
- Gilead$223
- Takeda Pharmaceuticals U.S.A., Inc.$205
- Merck$174
- AbbVie$94
- Johnson & Johnson$58
- plus $197 from 9 others
Across 4 payments — averaging $17,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$70K
What the payments were for
- Food & beverage$95981%
- Education$22219%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 6 | $230 |
| Gilead | 14 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $205 |
| Merck | 9 | $174 |
| AbbVie | 4 | $94 |
| Johnson & Johnson | 3 | $58 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $47 |
| Shionogi Inc | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| CSL Behring | 1 | $20 |
| Janssen Products, LP | 1 | $20 |
| Boston Scientific | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $12 |
How this compares
$1,181 in reported general payments places this provider in the 80th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $39,131 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $37,007 |
| Daptomycin | 19 | $6,973 |
| Fosfomycin Tromethamine | 12 | $2,497 |
| CeftriaxoneCeftriaxone Sodium | 21 | $2,171 |
| Cefazolin Sodium | 19 | $981 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $490 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $487 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $288 |
| Clindamycin Hcl | 12 | $237 |
| Cephalexin | 14 | $141 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Pontiac
- Shamla KalyanPontiac$1K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Christopher CarpenterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.